Intellia Therapeutics (NTLA) Interest Expenses (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Interest Expenses of $96.8 million for Q1 2026, down 32.15% year-over-year from $142.7 million in Q1 2025, and up 193578.0% quarter-over-quarter from $50000.0 in Q4 2025.
Intellia Therapeutics (NTLA) Interest Expenses (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Interest Expenses for 12 consecutive years, with $96.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 32.15% year-over-year to $96.8 million; the TTM figure through Mar 2026 stood at $96.8 million (down 32.15% YoY), while the FY2025 annual figure was $914.6 million, up 16.78% from the prior year.
- Interest Expenses climbed to $96.8 million in Q1 2026 per NTLA's latest filing, from $50000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $454.8 million in Q4 2022 and bottomed at $50000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $89.1 million across 5 years, with a median of $59.4 million in 2023.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 99.03% — and 2025, when it jumped 945.79%.
- Intellia Therapeutics' Interest Expenses stood at $454.8 million in 2022, then sank by 92.1% to $35.9 million in 2023, then slumped by 99.03% to $350000.0 in 2024, then sank by 85.71% to $50000.0 in 2025, then surged by 193578.0% to $96.8 million in 2026.
- Business Quant data shows NTLA's Interest Expenses at $96.8 million in Q1 2026, $50000.0 in Q4 2025, and $117.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 86.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.82 Mn |
| Jun 30, 2026 | 86.82 Mn |
| Mar 31, 2026 | 96.84 Mn |
| Mar 31, 2026 | 96.84 Mn |
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 117.65 Mn |
| Sep 30, 2025 | 117.65 Mn |
| Jun 30, 2025 | 15.64 Mn |
| Jun 30, 2025 | 15.64 Mn |
| Mar 31, 2025 | 142.73 Mn |
| Mar 31, 2025 | 142.73 Mn |
| Dec 31, 2024 | 350,000.00 |
| Dec 31, 2024 | 350,000.00 |
| Sep 30, 2024 | 11.25 Mn |
| Sep 30, 2024 | 11.25 Mn |
| Jun 30, 2024 | 15.82 Mn |
| Jun 30, 2024 | 15.82 Mn |
| Mar 31, 2024 | 27.62 Mn |
| Mar 31, 2024 | 27.62 Mn |